Industry News

The Department of Health occupied its 5,285-sf BSL-3 laboratory in Washington, D.C., on May 29, 2008. Planning for the $9.6 million project began in 1999. The facility will support rapid identification of emerging disease agents and potential biological threats with the capacity to perform up to 30,000 tests per year.

The Hunan Provincial Government is partnering with Microbix Biosystems to construct an influenza vaccine manufacturing complex in the Hunan Liuyang Biomedical Industrial Park in China. The $200-million jointly-owned project, one of the largest flu vaccine production facilities worldwide, will be managed by Microbix and will utilize the company’s VIRUSMAX technology.

Tufts University is building the $25.9 million Regional Biocontainment Laboratory in North Grafton, Mass. Part of the Cummings School of Veterinary Medicine, the facility is funded in part by $19.35 million from the National Institute of Allergy and Infectious Diseases. The 38,000-gsf facility is sited on 5.4 acres in the Grafton Science Park and will include 23,290-sf of mechanical and basement space.

Ark Therapeutics Group opened a $19.1 million GMP-3 manufacturing facility in Kuopio, Finland, in July of 2008. The commercial scale production plant is connected to Ark's existing laboratory suites and will manufacture gene-based medicines. The BSL-2 facility features a 547-sm cleanroom with HEPA air filtration. The duration of construction for the project was three years.

The University of Minnesota will construct a plant pathogen laboratory with greenhouses on its St. Paul campus. The project was approved by the USDA’s Animal and Plant Health Inspection Service in June of 2008 and will accommodate research on diseases such as the virulent stem rust Ug99. The secure facility will feature advanced air filtration and containment technologies.